Moreover, in patients with severe congenital neutropenia, 1,25(OH)2D was found to induce pro-LL-37 expression in neutrophil precursors and transformed B cells, highlighting its potential as a therapeutic strategy [40]. The gene discussed is CAMP; the disease is severe congenital neutropenia.